Development of DENVax: A chimeric dengue-2 PDK-53-based tetravalent vaccine for protection against dengue fever.

Osorio JE, Huang CY, Kinney RM, Stinchcomb DT.

Source

Inviragen, Inc., Fort Collins, CO 80525, and Madison, WI 53719, USA; Department of Pathobiological Sciences, University of Wisconsin-Madison, School of Veterinary Medicine, Madison, WI 53706, USA.

Abstract

Dengue. virus infection is the leading arboviral cause of disease worldwide. A vaccine is being developed based on the attenuated DEN-2 virus, DEN-2 PDK-53. In this review, we summarize the characteristics of the parent DEN-2 PDK-53 strain as well as the chimeric viruses containing the prM and E genes of DEN-1, DEN-3 or DEN-4 virus in the genetic backbone of the DEN-2 PDK-53 virus (termed DENVax). Tetravalent DENVax formulations containing cloned, fully sequenced isolates of the DEN-2 PDK-53 virus and the three chimeras have been evaluated for safety and efficacy in preclinical animal models. Based on the safety, immunogenicity and efficacy in preclinical studies, Phase 1 clinical testing of DENVax has been initiated.
Copyright © 2011 Elsevier Ltd. All rights reserved.